John is a Senior Scientist within the High Content Imaging group of Quantitative Biosciences at Merck in Boston, USA. He trained as a pharmacist and worked as a consultant pharmacist before receiving his PhD at The University of Queensland, Australia. Here John applied high content imaging to investigate dynamic calcium signaling alterations in breast cancer. He completed his postdoctoral fellowship at Merck where he advanced an in vitro profiling model for the prediction of drug-induced clinical cardiac adverse effects. Currently as a Senior Scientist at Merck, he supports early drug discovery efforts for multiple disease areas using predominantly high content imaging approaches.